The Filing Desk

Septerna

SEPN · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

SEPN · Last close · November 13, 2026
$42.60
Value Septerna yourself

Septerna's revenue rose 4174.5% to $46 million in fiscal 2025. Its operating margin was −148.6%, up from −7,518.4% a year earlier. Free cash flow was $110 million. The diluted share count rose 347.5%.

Septerna, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 9, 2026 · 0001193125-26-098507 Updated
Revenue
$46M
4174.5%
Operating margin
−148.6%
7369.8 pts
Net income
−$49M
 
Free cash flow
$110M
 
Return on equity
−12.2%
25.4 pts
Market cap
$2.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Septerna does

Septerna is a clinical-stage biotechnology company that discovers oral small-molecule drugs aimed at GPCRs. These are proteins in cell membranes that detect signals and relay them into the cell. They affect nearly every organ system, and many approved drugs already target them. Septerna says many possible GPCR targets have not yet been tapped for drugs.

The company has no approved products and does not sell any. Its method is its proprietary Native Complex Platform, which reproduces GPCRs outside cells in their natural shape so researchers can study them and find molecules that bind to them. Its own programs focus first on endocrinology, immunology and inflammation, and metabolic diseases. Its lead programs include an oral drug candidate, SEP-479, for hypoparathyroidism, a condition of low parathyroid hormone, and a candidate called SEP-631.

Its income comes from partners rather than from sales. In May 2025 it signed a collaboration and license agreement with Novo Nordisk on metabolic disease targets. Novo paid an upfront fee in July 2025, and Septerna can receive milestone payments and other payments if programs advance. Septerna keeps all other rights to its platform and programs.

Its biggest risks, as it describes them

  • A short operating history and large losses, which it expects to continue.
  • Needing substantial additional funding to run its business.
  • Being early in development, with no advanced clinical trials completed, so a product may be years away or never come.
  • Clinical trials that may be delayed or fail to show safety and effectiveness.
  • Reliance on outside manufacturers, research organizations and suppliers.
From Septerna's annual report on Form 10-K, filed March 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Septerna lost money in fiscal 2025: a net loss of $49 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments88351391
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage———
Current ratio16.3x27.8x4.7x
Quick ratio16.3x27.8x4.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Septerna's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Septerna reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 40−5,860.0%4,413.2%
Altman Z''14.993.75
Accruals ratio−1.5%−30.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailPass
Return on assets rose—Pass
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rosePassFail
Share count didn't riseFailFail
Gross margin rose——
Revenue rose relative to assets—Pass
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Septerna side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
SepternaFY254,174.5%−148.6%238.7%———
Protagonist TherapeuticsFY25−89.4%−343.6%121.9%———Compare
Wave Life SciencesFY25−60.5%−504.1%−440.5%———Compare
Editas MedicineFY2525.4%−394.9%−409.3%——2Compare
Kymera TherapeuticsFY25−16.7%−891.1%−597.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue0146
Revenue growth—611.9%4,174.5%
Gross profit———
Research and development366598
Operating income2−81−68
Net income4−72−49
Diluted EPS (US$)0.29−7.26−1.10
Diluted shares (millions)21044
Cash flow
Cash from operations−39−68110
Capital expenditure320
Free cash flow−42−70110
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation238
Balance sheet at fiscal year end
Cash and short-term investments88351391
Debt incl. finance leases———
Total assets131457596
Total liabilities2036214
Shareholders' equity−38420382
Margins and ratios
Gross margin———
Operating margin1,374.2%−7,518.4%−148.6%
Net margin2,768.2%−6,678.9%−106.4%
Free cash flow margin−27,550.3%−6,471.9%238.7%
Rule of 40 (growth + FCF margin)—−5,860.0%4,413.2%
Return on capital———
Return on equity—−37.6%−12.2%
Return on assets—−24.4%−9.3%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Septerna's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Septerna.